ArticleJournal of human immunity2026
Shared TCR Vβ21.3+ T cell immunological signature between MIS-A and MIS-C.
Article in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multisystem inflammatory syndrome (MIS) is a severe and potentially life-threatening complication of SARS-CoV-2 infection that affects both children (MIS-C) and adults (MIS-A). While the inflammatory response in MIS-C has been studied in detail, the immune dysregulation underlying MIS-A remains poorly understood, mainly due to the rarity of its condition. Using flow cytometry, we analyzed the T cell response in two, Danish and French, MIS-A cohorts, encompassing a total of 16 cases. We observed an expansion of Vβ21.3+ T cells in at least one of the major T cell subsets (CD3+, CD4+, or CD8+) in 9 out of 16 MIS-A patients. Vβ21.3+ T cells showed increased expression of activation and exhaustion markers along with a higher abundance of effector memory T cells compared to their Vβ21.3-negative counterparts in patients with or without Vβ21.3 expansion. These findings demonstrate that MIS-A shares the same Vβ21.3+ T cell signature previously reported in MIS-C, suggesting a shared pathological immune-related mechanism between the two conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.